Microbially triggered drug delivery to the colon

European Journal of Pharmaceutical Sciences

Volumn 18, Issue 1, 2003, Pages 3-18

  Sinha, V R ^a   Kumria, Rachna ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Colon targeting; Colon specific drug delivery; Microflora; Polysaccharides; Prodrugs

Indexed keywords

BACTERIA; BIODIVERSITY; BIOLOGICAL ORGANS; DRUG DOSAGE; MOLECULES; PROTEINS;

COLON;

DRUG PRODUCTS;

4 AMINOBENZOYL BETA ALANINE; 4 AMINOHIPPURIC ACID; 9 AMINOCAMPTOTHECIN; ALANINE; AMINOSALICYLIC ACID; BUDESONIDE; DEXAMETHASONE; DEXTRO ALANINE; DRUG CARRIER; FLUDROCORTISONE; GALACTOSE; GLUCOSE; GLUCURONIC ACID; GLUTAMIC ACID; GLYCINE; HYDROCORTISONE; MENTHOL; METHIONINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NALMEFENE; NALOXONE; POLYMER; PREDNISOLONE; PRODRUG; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SULFAPYRIDINE; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL METABOLISM; CLOSTRIDIUM PERFRINGENS; COLIFORM BACTERIUM; COLON; DRUG ABSORPTION; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG RELEASE; DRUG TARGETING; ENTERITIS; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; EUKARYOTIC CELL; FUNGUS; FUSOBACTERIUM; GASTROINTESTINAL TRACT; GRAM NEGATIVE BACTERIUM; HUMAN; INTESTINE ABSORPTION; INTESTINE FLORA; LACTOBACILLUS; LARGE INTESTINE; MICROBIAL ACTIVITY; MICROFLORA; MOUTH CAVITY; NONHUMAN; PEPTOSTREPTOCOCCUS; PERISTALSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SMALL INTESTINE; STAPHYLOCOCCUS; STOMACH; VEILLONELLA;

ADMINISTRATION, ORAL; ANIMALS; COLON; DRUG DELIVERY SYSTEMS; ECOSYSTEM; HUMANS; PEPTIDES; PHARMACEUTICAL PREPARATIONS; POLYMERS; PRODRUGS; TABLETS, ENTERIC-COATED; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037243915     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(02)00221-X     Document Type: Review

References (158)

1. Adkin A.D., Kenyon C.J., Lerner E.I., Landau I., Strauss E., Caron D., Penhasi A., Rubinstein A., Wilding I.R. The use of scintigraphy to provide 'proof of concept' for novel polysaccharide preparation designed for colonic drug delivery. Pharm. Res. 14:1997;103-107.
2. Ahrabi S.F., Madsen G., Dyrstad K., Sande S.A., Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur. J. Pharm. Sci. 10:2000;43-52.
3. Aiedeh K., Taha M.O. Synthesis of chitosan succinate and chitosan phthalate and their evaluation as suggested matrices in orally administered, colon specific drug delivery system. Arch. Pharm. (Weinheim). 332:1999;103-107.
4. Ashford M., Fell J.T., Attwood D., Sharma H.L., Woodhead P.J. An evaluation of pectin as a carrier for drug targeting to the colon. J. Control. Release. 26:1993;213-220.
5. Ashford M., Fell J.T., Attwood D., Sharma H.L., Woodhead P.J. Studies on pectin formulation for colonic drug delivery. J. Control. Release. 30:1994;225-232.
6. Bannister L.H. The alimentary canal. Williams P.L. Gray's Anatomy. The Anatomical Basis of Medicine and Surgery. 1995;1683-1812.
7. Barbara H., Friend D.R. Anatomy and physiology of the GI tract. Friend D.R. Oral Colon Specific Drug Delivery. 1992;1-44.
8. Bauer K.H., Kesselhut J.F. Novel pharmaceutical excipients for colon targeting. STP Pharm. Sci. 5:1995;54-59.
9. Bayliss C.E., Houston A.P. Degradation of guar gum by faecal bacteria. Appl. Environ. Microbiol. 48:1986;626-632.
10. Boxenbaum H.G., Bekersky I., Jack M.L., Kaplan S.A. Influence of gut microflora on bioavailability. Drug Metab. Rev. 9:1979;259-279.
11. Brondsted H., Kopecek J. Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation. Pharm. Res. 9:1992;1540-1545.
12. Brondsted H., Hovgaard L., Simonsen L. Dextran hydrogels for colon specific drug delivery. III. In vitro and in vivo degradation. STP Pharm. 5:1995;60-64.
13. Brondsted H., Andersen C., Hovgaard L. Cross linked dextran - a new capsule material for colon targeting of drug. J. Control. Release. 53:1998;7-13.
14. Brown J.P., McGarraugh G.V., Parkinson T.M., Wingard R.E. Jr., Onderdonk A.B. A polymeric drug for treatment of inflammatory bowel disease. J. Med. Chem. 26:1983;1300-1307.
15. Chan R.P., Pope D.J., Gilbett A.P., Sneta P.J., Baron J.H., Bennard Jones J.F. Studies of two novel sulphasalazine analogs ipsalazide and balsalazide. Dig. Dis. Sci. 28:1983;609-716.
16. Chavan M.S., Sant V.P., Nagarsenker M.S. Azo-containing urethane analogues for colonic drug delivery: synthesis, characterisation and in vitro evaluation. J. Pharm. Pharmacol. 53:2001;895-900.
17. Chiu H.C., Hsiue G.H., Lee Y.P., Huang L.W. Synthesis and characterization of pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system. J. Biomater. Sci. Polym. 10:1999;591-608.
18. Collins M.D., Gibson G.R. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am. J. Clin. Nutr. 69:1999;1052s-1057s.
19. Cui N., Friend D.R., Fedora R.N. A budesonide prodrug accelerates treatment of colitis in rats. Gut. 35:1994;1439-1446.
20. Cummings J.H., Englyst H.N. Fermentation in the human large intestine and the available substrates. Am. J. Clin. Nutr. 45:1987;1243-1255.
21. Cummings J.H., Macfarlane G.T. The control and consequences of bacterial fermentation in the human colon. J. Appl. Bacteriol. 70:1991;443-459.
22. 13C]glucose microspheres as a model for drug delivery to the colon. J. Control. Release. 40:1996;123-131.
23. Donaldson R.M. Role of indigenous enteric bacteria in intestinal function and disease. Code C.F. Handbook of Physiology. 1968;Williams and Wilkins, Baltimore.
24. Drasar B.S., Shiner M., McLeod G.M. Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. Gastroenterology. 56:1969;71-79.
25. Drasar B.S., Shiner M. Studies on the intestinal flora. II. Bacterial flora of the small intestine in patients with gastrointestinal disorders. Gut. 10:1969;812-819.
26. Dysseler P., Hoffem D. Inulin, an alternative dietary fiber. Properties and quantitative analysis. Eur. J. Clin. Nutr. 49:1995;S145-S152.
27. Englyst H.N., MacFarlane G.T. Breakdown of resistant and readily digestible starch of human gut bacteria. J. Sci. Food Agric. 37:1986;699-706.
28. Fernandez-Hervas M.J., Fell J.T. Pectin/chitosan mixtures as coatings for colon-specific drug delivery: an in vitro evaluation. Int. J. Pharm. 169:1998;115-119.
29. Finegold S.M., Sutter V.L., Sugihara P.T., Elder H.A., Lehman S.M., Phillips R.L. Fecal microbial flora in Seventh Day Adventist population and control subjects. Am. J. Clin. Nutr. 30:1977;1718-1792.
30. Friend D.R., Chang G.W. A colon-specific drug delivery system based on drug glycosides and glycosidase of colonic bacteria. J. Med. Chem. 27:1984;261-266.
31. Friend D.R., Chang G.W. Drug glycosides: Potential prodrugs for colon specific drug delivery. J. Med. Chem. 28:1985;51-57.
32. Friend D.R., Phillips S., McLeod A., Tozer T.N. Relative inflammatory effect of oral dexamethasone-β-D-glucoside and dexamethasone in experimental inflammatory bowel disease in guinea pig. J. Pharm. Pharmacol. 43:1991;353-355.
33. Friend D.R., Tozer T.N. Drug glycosides in oral colon-specific drug delivery. J. Control. Release. 19:1992;109-120.
34. Garretto M., Riddel R.H., Winans C.S. Treatment of chronic ulcerative colitis with poly-ASA: A new non-absorbable carrier for release of 5-aminosalicylate in the colon. Gastroenterology. 84:1983;1162-1164.
35. Gibson G.R., Beatty E.R., Wang X., Cummings J.H. Selective stimulation of Bifidobacteria in human colon by oligofructose and inulin. Gastroenterology. 108:1995;975-982.
36. Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 125:1995;1401-1414.
37. Gliko-Kabir I., Yagen B., Baluom M., Rubinstein A. Phosphated cross-linked guar for colon-specific drug delivery. II. In vitro and in vivo evaluation in the rat. J. Control. Release. 63:2000;129-134.
38. Goldman P. Biochemical pharmacology of the intestinal flora. Annu. Rev. Pharmacol. Toxicol. 18:1978;523-539.
39. Gomez A., Ladire M., Nardi M., Marcille F., Dabard J., Fons M. Molecular characterization of genes involved in the biosynthesis of antibiotic ruminococcin A by a Ruminococcus gnavus strain isolated from human intestinal flora; evidence for trypsin-mediated transcriptional regulation. Abstract of the General Meeting of the American Society for Microbiology 99. 1999;358-359.
40. Gorbach S.L., Plavt A.g., Nahas L., Weinstein L. Studies of intestinal microflora. II. Microorganism of the small intestine and their relations to oral and fecal flora. Gastroenterology. 53:1967;856-867.
41. Gorbach S.L., Nahas L., Lerner P.I. Studies of intestinal microflora. I. Effect of diet, age and periodic sampling on numbers of fecal microorganisms in man. Gastroenterology. 53:1967;845-850.
42. Gorbach S.L., Levitan R. Intestinal flora in health and in gastrointestinal diseases. Glass G.B.J. Progress in Gastroenterology. Vol. 2:1970;252-275 Grune and Stratton, New York.
43. Gorbach S.L. Intestinal microflora. Gastroenterology. 60:1971;1110-1129.
44. Grim Y., Kopecek J. Biodhesive water-soluble drug carriers for site specific oral drug delivery. Synthesis and characterization, and release of 5-aminosalicylic acid by Streptococcus faecium in vitro. New Polym. Mater. 3:1991;49-59.
45. Haeberlin B., Rubas W., Nolen III H.W., Friend D.R. In vitro evaluation of dexamethasone-β-D-glucuronide for colon-specific drug delivery. Pharm. Res. 10:1993;1553-1562.
46. Harboe E., Larsen C., Johansen M., Olesen H.P. Macromolecular prodrug. XIV. Absorption characteristics of naproxen after oral administration of dextran T-70-naproxen ester prodrug in pigs. Int. J. Pharm. 53:1989;157-165.
47. Harboe E., Larsen C., Johansen M., Olesen H.P. Macromolecular prodrug. XV. Colon-targeted delivery-bioavailability of naproxen from orally administered dextran-naproxen ester prodrugs varying in molecular size in the pig. Pharm. Res. 6:1989;919-923.
48. Harboe E., Larsen C., Johansen J. Macromolecular prodrug. X. Bioavailability of naproxen after oral administration of dextran-naproxen ester conjugates in rabbits. Farmaci Sci. Ed. 16:1988;65-72.
49. Hehre E.J., Sery T.W. Dextran splitting anaerobic bacteria from the human intestine. J. Bacteriol. 63:1952;424-426.
50. Hill M.J., Drasar B.S. The normal colonic bacterial flora. Gut. 16:1975;318-323.
51. Hirsch S., Binder V., Kolter K., Kesselhut J.F., Bauer K.H. Lauroyldextran as a coating material for site-specific drug delivery to the colon: in vitro dissolution of coated tablets. Proc. Int. Symp. Control. Release Bioact. Mater. 24:1997;379-380.
52. Hovgaard L., Brondsted H. Current applications of polysaccharides in colon targeting. Crit. Rev. Ther. Drug Carrier Syst. 13:1996;185-223.
53. Hungate R.E. Bacterial ecology in the small intestine. Am. J. Clin. Nutr. 31:1978;S125-S127.
54. Iglewski W.J., Gerhardt N.B. Identification of an antibiotic producing bacterium from the human intestinal tract and characterization of its antimicrobial product. Antimicrob. Agents Chemother. 13:1978;81-89.
55. Jung Y.J., Lee J.S., Kim H.H., Kim Y.K., Han S.K. Synthesis and evaluation of 5-aminosalicylglycine as a potential colon specific prodrug of 5-aminosalicylic acid. Arch. Pharmacol. Res. 21:1998;174-178.
56. Kakoulides E.P., Smart J.D., Tsibouklis J. Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity: in vitro degradation and preliminary ex vivo bioadhesion studies. J. Control. Release. 54:1998;95-109.
57. Kasper H. Protection against gastrointestinal diseases - present facts and future developments. Int. J. Food Microbiol. 41:1998;127-131.
58. Keighley M.R.B., Arabi Y., Dimock F., Burdon D.W., Allan R.N., Alexander-Williams J. Influence of inflammatory bowel disease on intestinal microflora. Gut. 19:1978;1099-1106.
59. Kenyon C.J., Nardi R.V., Wong D., Hooper G., Wilding I.R., Friend D.R. Colonic delivery of dexamethasone: a pharmacoscintigraphic evaluation. Aliment. Pharmacol. Ther. 11:1997;205-213.
60. Khan A.K.A., Piris J., Truelone S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 2:1977;895-896.
61. Kinget R., Kalala W., Vervoort L., Mooter G.U. Colonic drug targeting. J. Drug Target. 6:1998;129-149.
62. Kopecek J., Kopeckova P., Brondsted H., Rathi R., Rihova B., Yeh P.Y., Ikesue K. Polymers for colon-specific drug delivery. J. Control. Release. 19:1992;121-130.
63. Krishnaiah Y.S.R., Satyanarayana S., Rama Prasad Y.V., Narasimha Rao S. Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. J. Control. Release. 55:1998;245-252.
64. Krishnaiah Y.S.R., Satyanaryana S., Rama Prasad Y.V. Studies of guar gum compression-coated 5-aminosalicylic acid tablets for colon-specific drug delivery. Drug. Dev. Ind. Pharm. 25:1999;651-657.
65. Lashner B.A., Savina P.M., Garetto M., Kotale A.N., Bushby M.B., Blum M.R., Winans C.S. Release of 5-aminosalicylic acid (5-ASA) from BW73Y: in vitro and in vivo studies in humans. Gastroenterology. 86:1985;1154-1162.
66. Lee J.S., Jung Y.J., Doh M.J., Kim Y.M. Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev. Ind. Pharm. 27:2001;331-336.
67. Leopold C.S., Friend D.R. In vitro study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. Int. J. Pharm. 126:1995;139-145.
68. Leopold C.S., Friend D.R. In vivo pharmacokinetics study for the assessment of poly(L-aspartic acid) as a drug carrier for colon specific drug delivery. J. Pharmacokinet. Biopharm. 23:1995;397-406.
69. Leopold C.S. Coated dosage forms for colon-specific drug delivery. Pharm. Sci. Technol. Today. 2:1999;197-204.
70. Leopold C.S. Basic coating polymers for the colon specific drug delivery in Inflammatory bowel disease. Drug Dev. Ind. Pharm. 26:2000;1239-1246.
71. Lorenzo-Lamosa M.L., Remunan-Lopez C., Vila-Jato J.L., Alonson M.J. Design of microencapsulated chitosan microspheres for colonic drug delivery. J. Control. Release. 52:1998;109-118.
72. Macfarlane G.T., Hay S., Macfarlane S., Gibson G.R. Effect of different carbohydrates on growth, polysaccharidase and glycosidase production of Bacteroides ovatus in batch and continuous culture. J. Appl. Bacteriol. 68:1990;179-187.
73. MacLeod G.S., Fell J.T., Collett J.H., Sharma H.L., Smith A.M. Selective drug delivery to the colon using pectin:chitosan:hydroxypropyl methylcellulose film coated tablets. Int. J. Pharm. 187:1999;251-257.
74. MacLeod G.S., Fell J.T., Collett J.H. An in vitro investigation into the potential for biomodal drug release from pectin/chitosan HPMC-coated tablets. Int. J. Pharm. 188:1999;11-18.
75. Macy J.M. The biology of gastrointestinal Bacteroides. Annu. Rev. Microbiol. 33:1979;561-594.
76. Majamaa H., Isolauri E. Probiotics: a novel approach in the management of food allergy. J. Allergy Clin. Immunol. 99:1997;179-185.
77. Maris B., Verheyden L., Van Reeth K., Samyn C., Augustijns P., Kinget R., Van den Mooter G. Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting. Int. J. Pharm. 213:2001;143-152.
78. McBee R.H. Metabolic contributions of the cecal flora. Am. J. Clin. Nutr. 23:1970;1514-1518.
79. McKellar R.C., Modler H.W. Metabolism of fructooligosaccharides by Bifidobacterium spp. Appl. Microbiol. Biotechnol. 31:1989;537-541.
80. McLeod A.D., Friend D.R., Tozer T.N. Glucocorticoid-dextran conjugate as potential prodrug for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents. J. Pharm. Sci. 83:1994;1284-1288.
81. Milojevic S., Newton J.M., Cummings J.H., Gibson G.R., Botham R.L., Ring S.G., Stockham M., Allwood M.C. Amylose as a coating for drug delivery to the colon: Preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J. Control. Release. 38:1996;75-84.
82. Milojevic S., Newton J.M., Cummings J.H., Gibson G.R., Botham R.L., Ring S.G., Stockham M., Allwood M.C. Amylose as a coating for drug delivery to the colon: Preparation and in vitro evaluation using glucose pellets. J. Control. Release. 38:1996;85-94.
83. Minami K., Hirayama F., Uekama K. Colon specific drug delivery based on cyclodextrin prodrug: Release behaviour of biphenylyl acetic acid from its cyclodextrin conjugates in rat intestinal tract after oral administration. J. Pharm. Sci. 87:1998;715-720.
84. Moore W.E.C., Holdeman L.V. Human fecal flora: the normal flora of twenty Japanese-Hawaiians. Appl. Microbiol. 27:1974;961-979.
85. Moore W.E.C., Holdeman L.V. Discussion of current bacteriologic investigation of the relationships between intestinal flora, diet and colon cancer. Cancer Res. 35:1975;3418-3420.
86. Munjeri O., Collett J.H., Fell J.T. Hydrogel beads based on amidated pectins for colon-specific drug delivery: the role of chitosan in modifying drug release. J. Control. Release. 46:1997;273-278.
87. Nakamura J., Kido M., Nishida K., Sasaki H. Hydrolysis of salicylic acid tyrosine salicylic acid-methionine prodrugs in rabbits. Int. J. Pharm. 87:1992;59-66.
88. Nakamura J., Tagami C., Nishida K., Sasaki H. Unequal hydrolysis of salicylic acid-D-alanine and salicylic acid-L-alanine conjugate in rabbit intestinal microorganisms. Chem. Pharm. Bull. 40:1992;547-549.
89. Nakamura J., Asai P., Nishida K., Sasaki H. A novel prodrug of salicylic acid, salicylic acid-glutamic acid conjugate utilizing hydrolysis in rabbit intestinal microorganisms. Chem. Pharm. Bull. 40:1992;2164-2168.
90. Nakamura J., Kido M., Nishida K., Sasaki H. Effect of oral pretreatment with antibiotics on the hydrolysis of salicylic acid tyrosine and salicylic acid methionine prodrugs in rabbit intestinal microorganisms. Chem. Pharm. Bull. 40:1992;2572-2576.
91. Nolen H.W., Friend D.R. Menthol-β-D-glucuronide: A potential prodrug for treatment of the irritable bowel syndrome. Pharm. Res. 11:1994;1707-1711.
92. Rama Prasad Y.V., Krishnaiah Y.S., Satyanarayana S. In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. J. Control. Release. 51:1998;281-287.
93. Ring S.G., Gee J.M., Whittam M., Orford P., Johnson I.T. Resistant starch. Its chemical form in food stuffs and effects on digestibility in vitro. Food Chem. 28:1988;97-109.
94. Roberfroid M.B. Dietary fiber, inulin and oligofructose: a review comparing their physiological effects. Crit. Rev. Food. Sci. Nutr. 33:1993;103-148.
95. Rodrigues C.M.P., Kren B.T., Steer C.J., Setchell K.D.R. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulphate conjugation. Gastroenterology. 109:1995;1835-1844.
96. Roediger W.E.W. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 21:1980;793-798.
97. Roediger W.E.W., Moore A. Effect of short chain fatty acids in sodium absorption in isolated human colon perfused through the vascular bed. Dig. Dis. Sci. 26:1981;100-106.
98. Roediger W.E.W. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology. 83:1982;424-429.
99. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm. Drug Dispos. 11:1990;465-475.
100. Rubinstein A., Nakar D., Sintov A. Chondroitin sulphate: A potential biodegradable carrier for colon-specific drug delivery. Int. J. Pharm. 84:1992;141-150.
101. Rubinstein A., Nakar D., Sintov A. Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content. Pharm. Res. 9:1992;276-278.
102. Rubinstein A., Radai R., Ezra M., Pathak S., Rokem J.S. In vitro evaluation of calcium pectinate: A potential colon-specific drug delivery carrier. Pharm. Res. 10:1993;258-263.
103. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 12:1995;101-149.
104. Rubinstein A., Gliko-Kabir I. Synthesis and swelling dependent enzymatic degradation of borax modified guar gum for colonic delivery purpose. STP Pharm. Sci. 5:1995;41-46.
105. Rubinstein A., Gliko-Kabir I. Synthesis and swelling dependent enzymatic degradation of borax modified guar gum for colonic delivery purpose. STP Pharm. Sci. 5:1995;41-46.
106. Rubinstein A., Radai R. In vitro and in vivo analysis of colon specificity of calcium pectinate formulations. Eur. J. Pharm. Biopharm. 41:1995;291-295.
107. Ruppin H., Bar-Meir S., Soergel K.H., Wood C.M., Schmitt M.G. Absorption of short chain fatty acids by the colon. Gastroenterology. 78:1980;1500-1507.
108. Saffran M., Kumar G.S., Savarioar C., Burnham J.C., Williams F., Neekers D.C. A new approach to the oral administration of insulin and other peptide drugs. Science. 233:1986;1081-1084.
109. Saffran M., Bedra C., Kumar G.S., Neckers D.C. Vasopressin: A model for the study of effects of additives on the oral and rectal administration of peptide drugs. J. Pharm. Sci. 77:1988;33-38.
110. Saffran M., Field J.B., Pena J., Jones R.H., Ohuda Y. Oral insulin in diabetic dogs. J. Endocrinol. 131:1991;267-278.
111. Sakuma S., Lu Z.R., Kopeckova P., Kopecek J. Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. J. Control. Release. 75:2001;365-379.
112. Salminen S., Isolauri E., Onnela T. Gut Flora in normal and disordered states. Chemotherapy. 41:(Suppl. 1):1995;5-15.
113. Salyers A.A., Vercellotti J.R., West S.E.H., Wilkins T.D. Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl. Environ. Microbiol. 33:1977;319-322.
114. Salyers A.A., Palmer J.K., Wilkins T.D. Degradation of polysaccharides by intestinal bacterial enzymes. Am. J. Clin. Nutr. 31:1978;S128-S130.
115. Salyers A.A. Energy sources of major intestinal fermentative anaerobes. Am. J. Clin. Nutr. 32:1979;158-163.
116. Salyers A.A., Brien M. Cellular location of enzymes involved in chondroitin sulfate breakdown by Bacteroides thetaiotaomicron. J. Bacteriol. 143:1980;772-780.
117. Savage D.C. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. 31:1977;107-133.
118. Savage D.C. Interactions between the host and microbes. Clarke R.T.J., Bauchop T. Microbial Ecology of the Gut. 1977;277 Academic Press, New York.
119. Schacht E., Gevaert A., Refaie E.I., Kenawy M.K.W., Verstraete W., Adriaensens P., Carleer R., Gelan J. Polymers for colon-specific drug delivery. J. Control. Release. 39:1996;327-338.
120. Scheline R.R. Metabolism of foreign compounds by gastrointestinal microorganism. Pharmacol. Rev. 25:1973;451-523.
121. Semde R., Amighi K., Pierre D., Devleeschouwer M.J., Moes A.J. Leaching of pectin from mixed pectin/insoluble polymer films intended for colonic drug delivery. Int. J. Pharm. 174:1998;33-241.
122. Semde R., Amighi K., Devleeschouwe M.J., Moes A.J. Effect of pectinolytic enzymes on the theophylline release from pellets coated with water insoluble polymers containing pectin HM or calcium pectinate. Int. J. Pharm. 197:2000;169-179.
123. ® RL/Eudragit NE film coating formulations intended for colonic drug delivery. Int. J. Pharm. 197:2000;181-192.
124. Shanta K.L., Ravichandran P., Rao K.P. Azo polymeric hydrogels for colon targeted drug delivery. Biomaterials. 16:1995;1313-1318.
125. Shibasaki J., Inoue Y., Kadoskai Y.K., Sasaki H., Nakamura J. Hydrolysis of salicyluric acid in rabbit intestinal microorganisms. J. Pharmacobio-Dyn. 8:1985;989-995.
126. Shifrine M., Phaff H.J. Antonie van Leeuwenhoek. J. Microbiol. Serol. 24:1958;193-209.
127. Shun Y.L., Ayres J.W. Calcium alginate beads as core carriers of 5-aminosalicylic acid. Pharm. Res. 9:1992;714-790.
128. Siew L.F., Basit A.W., Newton J.M. The properties of amylose-ethylcellulose films cast from organic based solvents as potential coatings for colonic drug delivery. Eur. J. Pharm. Sci. 11:2000;133-139.
129. Siew L.F., Basit A.W., Newton J.M. The potential of organic based amylose ethylcellulose film coatings as oral colon-specific drug delivery systems. AAPS Pharm. Sci. Technol. 1:(3):2000;Article 22. ( http://www.pharmascitech.com ).
130. Simon G.L., Gorbach S.L. Intestinal flora in health and disease. Gastroenterology. 86:1984;174-193.
131. Simonsen L., Hovgaard L., Mortensen P.B., Brondsted H. Dextran hydrogels for colon-specific drug delivery. V. Degradation in human intestinal incubation models. Eur. J. Pharm. Sci. 3:1995;329-337.
132. Simpkins J.W., Smulkowski M., Dixon R., Tuttle R. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J. Pharmacol. Exp. Ther. 244:1988;195-205.
133. Sinha V.R., Kumria R. Colonic drug delivery: prodrug approach. Pharm. Res. 18:2001;557-564.
134. Sinha V.R., Kumria R. Polysaccharides in colon specific drug delivery. Int. J. Pharm. 224:2001;19-38.
135. Stanier Y.R., Adelberg E.A., Ingraham J. The Microbial Word. 4th Ed: 1976;Prentice-Hall, Englewood Cliffs, NJ.
136. Stirrup V., Evans D.F., Ledingham S., Thomas M., Pye G., Hardcastle J.D. Proceedings of the World Congress of Gastroenterology, Digestive Endoscopy, and Coloproctology, Sydney. 1990.
137. Thadepalli H., Lou M.A., Bach V.T. Microflora of the human small intestine. Am. J. Surg. 138:1979;845-850.
138. Tominaga, S., Takaizawa, T., Yamada, M., 1998. Colon drug delivery system. J. Pol. Appl. JP 10 324, 642 (98324,642) (Cl A61 K47/36); 8 Dec., 1998, JP Appl. 97/73, 599, 26 Mar., 1997, 9 PT (Japan).
139. Tomolin J., Taylor J.S., Read N.W. The effect of mixed faecal bacteria on a selection of viscous polysaccharide in vitro. Nutr. Rep. Int. 39:1989;121-135.
140. Tozaki H., Komoike J., Tada C., Maruyama T., Terabe A., Suzuki T., Yamamoto A., Muranishi S. Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon. J. Pharm. Sci. 86:1997;1016-1021.
141. Tozaki H., Fujita T., Odoriba T., Terabe A., Suzuki T., Tanaka C., Okabe S., Shoo Muranishi S., Yamamoto A. Colon specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: Therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. Life Sci. 64:1999;1155-1162.
142. Tozaki H., Fujita T., Komoike J., Kim S.I., Terashima H., Muranishi S., Okabe S., Yamamoto A. Colon-specific delivery of budesonide with azopolymer-coated pellets: Therapeutic effects of budesonide with a novel dosage form against 2,4,6,-trinitrobenzenesulphonic acid-induced colitis in rats. J. Pharm. Pharmacol. 51:1999;257-261.
143. Tozaki H., Nishioka J., Komoike J., Okada N., Fujita T., Muraanishi S., Kim S.I., Terashima H., Yamamoto A. Enhanced absorption of insulin and (Asu(1,7))eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery. J. Pharm. Sci. 90:2001;89-97.
144. A-[[(4-biphenylyl)acetyl]amino]-α-, -β- and -γ-cyclodextrins. Potential prodrugs for colon specific delivery. J. Med. Chem. 40:1997;2755-2761.
145. Van den Mooter G.V., Samyn C., Kinget R. In vivo evaluation of a colon specific drug delivery system: An absorption study of theophylline from capsules coated with azo polymers in rats. Pharm. Res. 12:1995;244-247.
146. Vervoort L., Kinget R. In vitro degradation by colonic bacteria of inulin HP incorporated in Eudragit films. Int. J. Pharm. 129:1996;185-190.
147. Vervoort L., Rambant P., Van den Mooter G., Augustijns P., Kinget R. Inulin hydrogels. II. In vitro degradation study. Int. J. Pharm. 172:1998;137-145.
148. Vilivalam V.D., Illum L., Iqbal K. Starch capsules: an alternative system for oral drug delivery. Pharm. Sci. Technol. Today. 3:2000;64-69.
149. Von Engelhardt W., Rechkemmer G. The physiological effects of short chain fatty acids in the hind gut. Bull. R. Soc. NZ. 20:1983;149-155.
150. Wakerly, Z., 1995. An investigation into citrus pectins for colonic drug delivery. Ph.D thesis, University of Manchester.
151. Wakerly Z., Fell J.T., Attwood D., Parkins D. Pectin/ethylcellulose film coating formulations for colonic drug delivery. Pharm. Res. 13:1996;1210-1212.
152. Wakerly Z., Fell J., Attwood D., Parkins D. Studies on amidated pectins as potential carriers in colonic drug delivery. J. Pharm. Pharmacol. 49:1997;622-625.
153. Wang X., Gibson G.R. Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. J. Appl. Bacteriol. 75:1993;373-380.
154. Watts P.J., Illum L. Colon drug delivery. Drug Dev. Ind. Pharm. 23:1999;893-913.
155. Werch S.C., Ivy A.C. On the fate of ingested pectin. Am. J. Digest. Dis. 8:1941;101-105.
156. Wilding I.R., Davis S.S., O'Hagan O.T. Targeting of drugs and vaccines to the gut. Pharmacol. Ther. 62:1994;97-124.
157. Willoughby C.P., Aronson J.K., Agback H., Bodin N.O., Truelove S.C. Distribution and metabolism in healthy volunteers of disodium azodisalicylate a potential therapeutic agent for ulcerative colitis. Gut. 23:1982;1081-1087.
158. Wong D., Larrabeo S., Clifford K., Tremblay J., Friend D.R. USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulation. J. Control. Release. 47:1997;173-179.